Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMODEL-WM3
2016-001033-27Phase 2Completed
- Sponsor
- Filo
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of idelalisib, obinutuzumab in Waldenström macroglobulinemia (WM), sponsored by Filo. Started Nov 2016; status: completed.
02
Drugs
idelalisibobinutuzumab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2016-001033-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001033-27.